Regina Maria Papais Alvarenga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Regina Maria Papais Alvarenga has a total of 364 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Cristina Ferreira Vasconcelos
Universidade Federal do Estado do Rio de Janeiro, Pós-Graduação Stricto Sensu em Neurologia, Rio de Janeiro RJ, Brazil
10 shared publications Claudia Cristina Ferreira Vasconcelos
Department of Neurology, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
9 shared publications- Luiz Claudio Santos Thuler
Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil
9 shared publications - Cleonice Alves Melo Bento
Department of Microbiology and Parasitology, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil; Post-graduate Program in Neurology and Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil; Department of General Medicine, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
6 shared publications Luiz Claudio Santos Thuler
Universidade Federal do Estado do Rio de Janeiro, Brasil; Instituto Nacional de Câncer, Brasil
6 shared publicationsMarcos Papais Alvarenga
6 shared publications
Latest Publications
- 26 June 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (7)
Hereditary gelsolin amyloidosis in Brazil: case report and brief review of the literature
- 26 June 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (7)
Hereditary gelsolin amyloidosis in Brazil: case report and brief review of the literature
- 7 April 2026
- Published by S. Karger AG in Neuroepidemiology
- p. 1-16
Global Prevalence of Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis with New Data from Rio de Janeiro, Brazil
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune astrocytopathy with geographic and ancestral variability in prevalence. Despite growing international epidemiological evidence, population-based prevalence studies of NMOSD remain scarce in Brazil. Objective: The aim of the study was to integrate global evidence from a systematic review and meta-analysis with new regional prevalence data from southeastern Brazil using complementary epidemiological and statistical methods. Methods: A systematic review was conducted to identify studies reporting crude NMOSD prevalence between 2000 and 2025. In parallel, a multi-source prevalence study was performed in the Volta Redonda-Barra Mansa intermediate region of Rio de Janeiro State. Crude prevalence, classical two-source capture-recapture estimators, and Bayesian modeling were applied. A random-effects meta-analysis combined international estimates with Brazilian data and compared pooled results across continents. Results: We identified 44 eligible studies from 28 countries, with substantial heterogeneity reflecting differences in diagnostic criteria, case-ascertainment strategies, and geographic coverage. Crude NMOSD prevalence ranged from 0.23 to 10.0 per 100,000 inhabitants. In the Brazilian regional study, 24 confirmed cases among 782,004 inhabitants yielded a crude prevalence of 3.07 per 100,000, with capture-recapture estimates ranging from 3.53 to 5.60 per 100,000 and Bayesian posterior mean estimates of 3.84–3.87 per 100,000. The global meta-analysis produced a pooled prevalence of 2.02 per 100,000 inhabitants, with continent-specific differences: the Americas showed the highest prevalence, followed by Asia, Europe, and Oceania. Conclusion: This study provides an integrated evaluation of NMOSD prevalence through a global systematic review, a regional population-based analysis in southeastern Brazil, and a meta-analysis, demonstrating that prevalence in this region is higher than the global pooled estimate and consistent with the higher prevalence observed in the Americas, particularly in populations with substantial African ancestral backgrounds.
- 7 April 2026
- Published by S. Karger AG in Neuroepidemiology
- p. 1-16
Global Prevalence of Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis with New Data from Rio de Janeiro, Brazil
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune astrocytopathy with geographic and ancestral variability in prevalence. Despite growing international epidemiological evidence, population-based prevalence studies of NMOSD remain scarce in Brazil. Objective: The aim of the study was to integrate global evidence from a systematic review and meta-analysis with new regional prevalence data from southeastern Brazil using complementary epidemiological and statistical methods. Methods: A systematic review was conducted to identify studies reporting crude NMOSD prevalence between 2000 and 2025. In parallel, a multi-source prevalence study was performed in the Volta Redonda-Barra Mansa intermediate region of Rio de Janeiro State. Crude prevalence, classical two-source capture-recapture estimators, and Bayesian modeling were applied. A random-effects meta-analysis combined international estimates with Brazilian data and compared pooled results across continents. Results: We identified 44 eligible studies from 28 countries, with substantial heterogeneity reflecting differences in diagnostic criteria, case-ascertainment strategies, and geographic coverage. Crude NMOSD prevalence ranged from 0.23 to 10.0 per 100,000 inhabitants. In the Brazilian regional study, 24 confirmed cases among 782,004 inhabitants yielded a crude prevalence of 3.07 per 100,000, with capture-recapture estimates ranging from 3.53 to 5.60 per 100,000 and Bayesian posterior mean estimates of 3.84–3.87 per 100,000. The global meta-analysis produced a pooled prevalence of 2.02 per 100,000 inhabitants, with continent-specific differences: the Americas showed the highest prevalence, followed by Asia, Europe, and Oceania. Conclusion: This study provides an integrated evaluation of NMOSD prevalence through a global systematic review, a regional population-based analysis in southeastern Brazil, and a meta-analysis, demonstrating that prevalence in this region is higher than the global pooled estimate and consistent with the higher prevalence observed in the Americas, particularly in populations with substantial African ancestral backgrounds.
- Open Access
- 10 December 2025
- Published by MDPI AG in Journal of Functional Morphology and Kinesiology
- Vol. 10 (4) , 477
Physical Function, Muscle Strength, and Fatigue in Patients with Multiple Sclerosis: An Exploratory Cross-Sectional Study
Background: Physical function, muscle strength, and fatigue are often impaired in patients with multiple sclerosis (MS). This study aimed to assess these parameters and their associations. Methods: This cross-sectional study included patients with relapsing-remitting MS. Physical function was assessed using the dynamic gait index (DGI), two-minute walk test (2MWT), and Expanded Disability Status Scale (EDSS). Muscle strength and fatigue were assessed using a load cell (measured in kgf). Generalized linear models (GLMs) with log link and gamma distribution examined the associations between MS and physical function, muscle strength, and fatigue. In the MS group, GLMs explored links between fatigue, muscle strength, and physical function. Results: Forty-seven individuals participated (18 MS; 27 controls). Patients with MS showed reduced physical function and muscle strength, and higher fatigue. Knee extension fatigue was associated with DGI (Exp β = 0.23; p = 0.03), 2MWT (Exp β = 0.11; p = 0.02), and EDSS (Exp β = 17.17; p < 0.0001); knee flexion fatigue was associated with EDSS (Exp β = 2.45; p = 0.006). Knee flexion and extension strength were also associated with EDSS. Conclusions: Patients with MS show reduced physical function and strength, increased fatigue, and knee muscle performance. The associations between strength, fatigue, and functional outcomes varied in magnitude, with knee-related measures, especially knee extension fatigue, showing the most consistent relationships.
- 10 December 2025
- Published by MDPI AG in Journal of Functional Morphology and Kinesiology
- Vol. 10 (4) , 477
Open AccessPhysical Function, Muscle Strength, and Fatigue in Patients with Multiple Sclerosis: An Exploratory Cross-Sectional Study
Background: Physical function, muscle strength, and fatigue are often impaired in patients with multiple sclerosis (MS). This study aimed to assess these parameters and their associations. Methods: This cross-sectional study included patients with relapsing-remitting MS. Physical function was assessed using the dynamic gait index (DGI), two-minute walk test (2MWT), and Expanded Disability Status Scale (EDSS). Muscle strength and fatigue were assessed using a load cell (measured in kgf). Generalized linear models (GLMs) with log link and gamma distribution examined the associations between MS and physical function, muscle strength, and fatigue. In the MS group, GLMs explored links between fatigue, muscle strength, and physical function. Results: Forty-seven individuals participated (18 MS; 27 controls). Patients with MS showed reduced physical function and muscle strength, and higher fatigue. Knee extension fatigue was associated with DGI (Exp β = 0.23; p = 0.03), 2MWT (Exp β = 0.11; p = 0.02), and EDSS (Exp β = 17.17; p < 0.0001); knee flexion fatigue was associated with EDSS (Exp β = 2.45; p = 0.006). Knee flexion and extension strength were also associated with EDSS. Conclusions: Patients with MS show reduced physical function and strength, increased fatigue, and knee muscle performance. The associations between strength, fatigue, and functional outcomes varied in magnitude, with knee-related measures, especially knee extension fatigue, showing the most consistent relationships.
- Open Access
- 28 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (11) , 001-021
2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children
Neuromyelitis optica spectrum disorder (NMOSD) is a debilitating recurrent inflammatory disease of the central nervous system. Establishing management guidelines is essential to optimize patient care in Brazil. To combine the Delphi and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approaches to validate evidence-based guideline statements for NMOSD treatment. These guidelines focused on providing recommendations for different scenarios: general management and diagnosis of NMOSD; acute and preventive treatments (including systemic immunosuppressants and anti-B cell, anti-interleukin-6, and anti-complement monoclonal antibodies); and therapeutic approaches in special groups (such as the pediatric population and pregnant women). A literature review based on the Population, Intervention, Comparator, and Outcome (PICO) framework was performed, and studies were evaluated using the GRADE system. An initial questionnaire containing 19 statements was sent to 44 specialists from all regions of Brazil. Three voting rounds were necessary to reach consensus in all statements. After the first voting round, 17 statements reached consensus (level of agreement > 70%). Two statements failed to reach consensus and were, thus, revised. One of them was segmented into three different statements. After the second voting round, three out of the four revised statements reached consensus. Upon further revision, the last statement was again submitted to voting, reaching consensus in this third round. Overall, agreement was achieved on the 21 proposed statements. The primary objective in the management of NMOSD is to mitigate the severity of the attacks and prevent relapses, thereby minimizing the risk of irreversible neurological deficits. The statements in the current guideline offer evidence-based recommendations for such management within the Brazilian context.
- 28 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (11) , 001-021
Open Access2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children
Neuromyelitis optica spectrum disorder (NMOSD) is a debilitating recurrent inflammatory disease of the central nervous system. Establishing management guidelines is essential to optimize patient care in Brazil. To combine the Delphi and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approaches to validate evidence-based guideline statements for NMOSD treatment. These guidelines focused on providing recommendations for different scenarios: general management and diagnosis of NMOSD; acute and preventive treatments (including systemic immunosuppressants and anti-B cell, anti-interleukin-6, and anti-complement monoclonal antibodies); and therapeutic approaches in special groups (such as the pediatric population and pregnant women). A literature review based on the Population, Intervention, Comparator, and Outcome (PICO) framework was performed, and studies were evaluated using the GRADE system. An initial questionnaire containing 19 statements was sent to 44 specialists from all regions of Brazil. Three voting rounds were necessary to reach consensus in all statements. After the first voting round, 17 statements reached consensus (level of agreement > 70%). Two statements failed to reach consensus and were, thus, revised. One of them was segmented into three different statements. After the second voting round, three out of the four revised statements reached consensus. Upon further revision, the last statement was again submitted to voting, reaching consensus in this third round. Overall, agreement was achieved on the 21 proposed statements. The primary objective in the management of NMOSD is to mitigate the severity of the attacks and prevent relapses, thereby minimizing the risk of irreversible neurological deficits. The statements in the current guideline offer evidence-based recommendations for such management within the Brazilian context.
- Open Access
- 22 August 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (8) , 886
Assessing the Impact of IL-6 and Serotonin on Pain and Symptomatology in Fibromyalgia: An Exploratory Clinical Study
Background and Objectives: Fibromyalgia (FM) is a chronic musculoskeletal pain syndrome characterized by widespread pain and a variety of other symptoms, including fatigue, cognitive dysfunction, and sleep disturbances. Recent research has highlighted the potential role of pro-inflammatory cytokines and neurotransmitters in the pathophysiology of FM. This study aimed to investigate the relationship between serum levels of interleukin-6 (IL-6) and serotonin with the clinical parameters observed in patients with fibromyalgia. Additionally, it sought to analyze the similarities and differences among the different groups classified by symptom severity. Materials and Methods: This cross-sectional study included 26 female patients aged 20–70 diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria and 14 healthy controls (HCs). Serum levels of IL-6 and serotonin were measured using electrochemiluminescence and high-performance liquid chromatography (HPLC), respectively. Results: FM patients exhibited significantly higher pain scores (VAS), anxiety, and depression levels compared to HCs. FIQ-R scores were significantly elevated in FM patients, with stratification showing 3.8% mild, 65.4% moderate, 23.1% severe, and 7.7% very severe cases. While no significant difference in IL-6 levels was observed between the FM patients and HCs, a trend towards increased IL-6 levels in patients with higher FIQ-R scores was noted. Serum serotonin levels were significantly lower in the FM patients than in the HCs, with moderate patients having lower levels than those classified as severe and very severe. Conclusions: The study underscores the potential role of IL-6 and serotonin in the pathophysiology of FM, suggesting that these biomarkers could be relevant in assessing the severity and impact of FM. Further research is needed to elucidate these relationships and their implications for developing personalized treatment strategies.
- 22 August 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (8) , 886
Open AccessAssessing the Impact of IL-6 and Serotonin on Pain and Symptomatology in Fibromyalgia: An Exploratory Clinical Study
Background and Objectives: Fibromyalgia (FM) is a chronic musculoskeletal pain syndrome characterized by widespread pain and a variety of other symptoms, including fatigue, cognitive dysfunction, and sleep disturbances. Recent research has highlighted the potential role of pro-inflammatory cytokines and neurotransmitters in the pathophysiology of FM. This study aimed to investigate the relationship between serum levels of interleukin-6 (IL-6) and serotonin with the clinical parameters observed in patients with fibromyalgia. Additionally, it sought to analyze the similarities and differences among the different groups classified by symptom severity. Materials and Methods: This cross-sectional study included 26 female patients aged 20–70 diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria and 14 healthy controls (HCs). Serum levels of IL-6 and serotonin were measured using electrochemiluminescence and high-performance liquid chromatography (HPLC), respectively. Results: FM patients exhibited significantly higher pain scores (VAS), anxiety, and depression levels compared to HCs. FIQ-R scores were significantly elevated in FM patients, with stratification showing 3.8% mild, 65.4% moderate, 23.1% severe, and 7.7% very severe cases. While no significant difference in IL-6 levels was observed between the FM patients and HCs, a trend towards increased IL-6 levels in patients with higher FIQ-R scores was noted. Serum serotonin levels were significantly lower in the FM patients than in the HCs, with moderate patients having lower levels than those classified as severe and very severe. Conclusions: The study underscores the potential role of IL-6 and serotonin in the pathophysiology of FM, suggesting that these biomarkers could be relevant in assessing the severity and impact of FM. Further research is needed to elucidate these relationships and their implications for developing personalized treatment strategies.
- Open Access
- 27 January 2023
- Published by Wiley in Brain and Behavior
- Vol. 13 (2) , e2891
Comparison between a handheld ultrasound device and a traditional ultrasound for performing transcranial sonography in patients with Parkinson's disease
Objective: The aim of this study is to compare a portable ultrasound (US) device and a traditional US for performing transcranial ultrasonography (CCT) in patients with Parkinson's disease (PD).Methods: This is a cross‐sectional, observational, and analytical study. The study recruited a total of 129 individuals from two public hospitals in the city of Rio de Janeiro in a prospective and non‐randomized manner between September 2019 and July 2021 as follows: group A with 31 patients with PD, group B with 65 patients with PD, and group C with 64 healthy individuals. Group A was used to collect data to establish the agreement analysis of the TCS measurements between the two devices. Groups B and C provided data for constructing the receiver operating characteristic curve for the handheld US. The subjects underwent the assessment of the transtemporal bone window (TW) quality, the mesencephalon area, the size of the third ventricle, and the substantia nigra (SN) hyperechogenicity area.Results: There was a good agreement between the methods regarding the quality of the TW–Kappa concordance coefficient of 100% for the right TW and 83% for the left, the midbrain area—intraclass correlation coefficient (ICC) of 69%, the SN area ICC = 90% for the right SN and 93% for the left and the size of the third ventricle ICC = 96%. The cutoff point for the SN echogenic area in the handheld US was 0.20 cm2.Conclusions: The handheld US is a viable imaging method for performing TCS because it shows good agreement with the measurements performed with traditional equipment, and the measurement of SN echogenic area for PD diagnosis presents good sensitivity and specificity.
- 27 January 2023
- Published by Wiley in Brain and Behavior
- Vol. 13 (2) , e2891
Open AccessComparison between a handheld ultrasound device and a traditional ultrasound for performing transcranial sonography in patients with Parkinson's disease
Objective: The aim of this study is to compare a portable ultrasound (US) device and a traditional US for performing transcranial ultrasonography (CCT) in patients with Parkinson's disease (PD).Methods: This is a cross‐sectional, observational, and analytical study. The study recruited a total of 129 individuals from two public hospitals in the city of Rio de Janeiro in a prospective and non‐randomized manner between September 2019 and July 2021 as follows: group A with 31 patients with PD, group B with 65 patients with PD, and group C with 64 healthy individuals. Group A was used to collect data to establish the agreement analysis of the TCS measurements between the two devices. Groups B and C provided data for constructing the receiver operating characteristic curve for the handheld US. The subjects underwent the assessment of the transtemporal bone window (TW) quality, the mesencephalon area, the size of the third ventricle, and the substantia nigra (SN) hyperechogenicity area.Results: There was a good agreement between the methods regarding the quality of the TW–Kappa concordance coefficient of 100% for the right TW and 83% for the left, the midbrain area—intraclass correlation coefficient (ICC) of 69%, the SN area ICC = 90% for the right SN and 93% for the left and the size of the third ventricle ICC = 96%. The cutoff point for the SN echogenic area in the handheld US was 0.20 cm2.Conclusions: The handheld US is a viable imaging method for performing TCS because it shows good agreement with the measurements performed with traditional equipment, and the measurement of SN echogenic area for PD diagnosis presents good sensitivity and specificity.
- 1 November 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 56, 103260
Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox
- 1 November 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 56, 103260
Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox
- Open Access
- 8 January 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-14
Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis
Neuromyelitis Optica and Multiple Sclerosis are idiopathic inflammatory demyelinating diseases of the central nervous system that currently are considered distinct autoimmune diseases, so differences in genetic susceptibility would be expected. This study aimed to investigate the HLA association with Neuromyelitis Optica by a systematic review with meta-analysis. The STROBE instrument guided research paper assessments. Thirteen papers published between 2009 and 2020 were eligible. 568 Neuromyelitis Optica patients, 41.4% Asians, 32.4% Latin Americans and 26.2% Europeans were analyzed. Only alleles of the DRB1 locus were genotyped in all studies. Neuromyelitis Optica patients have 2.46 more chances of having the DRB1*03 allelic group than controls. Ethnicity can influence genetic susceptibility. The main HLA association with Neuromyelitis Optica was the DRB1*03:01 allele in Western populations and with the DPB1*05:01 allele in Asia. Differences in the Multiple Sclerosis and Neuromyelitis Optica genetic susceptibility was confirmed in Afro descendants. The DRB1*03 allelic group associated with Neuromyelitis Optica has also been described in other systemic autoimmune diseases.
- 8 January 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-14
Open AccessNeuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis
Neuromyelitis Optica and Multiple Sclerosis are idiopathic inflammatory demyelinating diseases of the central nervous system that currently are considered distinct autoimmune diseases, so differences in genetic susceptibility would be expected. This study aimed to investigate the HLA association with Neuromyelitis Optica by a systematic review with meta-analysis. The STROBE instrument guided research paper assessments. Thirteen papers published between 2009 and 2020 were eligible. 568 Neuromyelitis Optica patients, 41.4% Asians, 32.4% Latin Americans and 26.2% Europeans were analyzed. Only alleles of the DRB1 locus were genotyped in all studies. Neuromyelitis Optica patients have 2.46 more chances of having the DRB1*03 allelic group than controls. Ethnicity can influence genetic susceptibility. The main HLA association with Neuromyelitis Optica was the DRB1*03:01 allele in Western populations and with the DPB1*05:01 allele in Asia. Differences in the Multiple Sclerosis and Neuromyelitis Optica genetic susceptibility was confirmed in Afro descendants. The DRB1*03 allelic group associated with Neuromyelitis Optica has also been described in other systemic autoimmune diseases.
- 1 November 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 46, 102424
CLINICAL course of acute disseminated encephalomyelitis in adults from Rio de Janeiro: Retrospective study of 23 cases and literature review
- 1 November 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 46, 102424
CLINICAL course of acute disseminated encephalomyelitis in adults from Rio de Janeiro: Retrospective study of 23 cases and literature review
- 1 July 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 42, 102082
Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
- 1 July 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 42, 102082
Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?